UK Artificial Intelligence firm signs license with Janssen for drug candidate

You are here: Home » Content Type » News » UK Artificial Intelligence firm signs license with Janssen for drug candidate9 November 2016  •  Author: Niamh Louise Marriott, Digital Content Producer BenevolentAI, a British artificial intelligence company has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen Pharmaceutica, a Johnson & Johnson company. BenevolentAI has acquired a license to a select number of novel clinical stage drug candidates and their extensive related portfolio of patents. BenevolentAI scientists leveraged the AI technology to evaluate the potential of these small molecule compounds. The results indicate that there is strong promise to develop new medicines for hard to treat diseases.  Under the terms of the license agreement, BenevolentAI will have the sole right to develop, manufacture and commercialise these…


Link to Full Article: UK Artificial Intelligence firm signs license with Janssen for drug candidate

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!